China's BCI Sector Accelerates: From 'Mind Control' to医保 Coding, a Critical Leap for Domestic Solutions
Sirrem
Intelligent Rehabilitation Robot Technology R&D Provider
On April 27, 2026, Sirrem, a brain-computer interface rehabilitation company, announced that it had completed a multi-million-yuan financing round, exclusively invested by Wuxi Liangxi Science and Innovation Industry Fund.
Recently, a series of significant financings have been completed within the same track, including Aowill Technology's C1 round of 150 million yuan financing and Step Medical's 500 million yuan strategic financing.
The capital-intensive move in this sector is not accidental either — when the annual number of patent applications related to brain-computer interfaces hit a new high of 547 in 2025, whenBeijing hasIncluding the cost of brain-computer interface implants in the scope of medical insurance reimbursement, this technology, which once only existed in science fiction movies, is now"China Speed" Enters a Key Window Period for Industrialization and Implementation.
Sirrem:
StructureBuild the Full StackTechnical Barriers
Sirrem was founded inHeadquartered in Ningbo in 2020, it is a rehabilitation technology enterprise that has simultaneously implemented both invasive and non-invasive brain-computer interface technologies, establishing a full closed-loop process of "EEG acquisition—AI decoding—flexible execution—cloud platform management." The company owns more than 80 core patents, and its products have received triple international certifications from NMPA, CE, and FDA. The technological maturity and compliance rank among the top in China's domestic industry.
In terms of technology layout, Sirrem has built"A Three-in-One Technical Matrix of 'Invasive + Non-invasive + Closed-loop Regulation'."
In the invasive aspect, the company has collaborated with top neuroscience teams in China to develop a high-density microelectrode array system. Dozens of clinical trials have been completed at Huashan Hospital in Shanghai, Jiangsu Provincial People's Hospital, and other institutions, helping高位截瘫 patients control finger movements such as grasping and releasing through thought.
In the non-invasive field, the company has launched three series of EEG acquisition devices: Nebula (high-density research-grade), Stellar Core (clinical-grade), and Halo (portable-grade), equipped with self-developed AI decoding algorithms. Clinical data shows that hand function scores improved by approximately 30% within five weeks.
In terms of product implementation, Sirrem's flexible rehabilitation robot has been deployed across China.Deployed in 200 tertiary hospitals and community rehabilitation centers, serving over ten thousand patients cumulatively. The company has also developed the industry's first brain-computer cloud rehabilitation platform, integrating hospital and home data to provide services such as remote assessment, prescription delivery, and real-time guidance. The average monthly cost of home rehabilitation is about one-tenth of traditional inpatient rehabilitation expenses.
This round of financing will be used for the deepening layout of the full-chain brain-computer interface rehabilitation product line, acceleration of clinical registration, construction of scaled production lines, and expansion of markets both in China and overseas.
Policies and Prices:
Medical Insurance Code Integration"The Critical Last Mile"
Behind Sirrem's financing is an industry ecosystem being systematically activated by policies and pricing systems. The resolution of the brain-computer interface charging issue has provided critical institutional support for the commercialization of the industry.
On March 31, 2025, under the guidance of the National Healthcare Security Administration, Hubei Province took the lead in introducing China's first medical service price program for brain-computer interface technology, specifying an invasive implantation fee of 6,552 yuan per session, establishing a charging basis for the clinical application of both non-invasive and invasive technical routes.
The Same YearIn September, the Guangdong Provincial Medical Insurance Bureau followed up with a notice, announcing that the fee for invasive insertion would be 6,600 yuan per session and the removal fee would be 3,200 yuan per session, to be implemented starting from September 30. Thus far, the Beijing-Tianjin-Hebei region and the Pearl River Delta region have successively established pricing systems for clinical charges related to brain-computer interface procedures.
In terms of price levels, different regions have established differentiated standards based on actual conditions: the government-guided prices for invasive brain-computer interface implantation fees in Beijing, Hubei, and Zhejiang are approximately7,000 yuan per session for invasive procedures, approximately 1,000 yuan per session for non-invasive; Jiangxi Province has set the fee for invasive implantation at 6,500 yuan per session, removal at 3,100 yuan, and non-invasive fitting at 960 yuan per session. Notably, Beijing has included brain-computer interface in the medical insurance reimbursement scope, with the implantation fee being fully reimbursable.
The relevant person in charge of the Department of Medicine Pricing and Bidding Procurement of the National Healthcare Security Administration stated that the standards for new price items are mainly considered from four aspects.——Whether the technology is mature, whether it is clinically needed, whether the industry can increase output, and whether the public and medical insurance funds can afford it. Professor Jiang Changsong from the National Institute of Healthcare Security Research at Capital Medical University commented: "Once the price is set, companies have a clear picture, they can calculate the return cycle for R&D investment, investors dare to follow, and hospitals have a basis for charging. This is the positive incentive that pricing projects have on the industry."
In March 2026, the world's first invasive brain-computer interface product was approved for marketing, and just two days later, the medical insurance code was implemented. This series of milestones indicates that China has basically established a complete process from laboratory research to hospital billing for brain-computer interfaces, providing clear expectations for enterprises, hospitals, and patients.
Patent Innovation:
Applications Reach a Ten-Year High in 2025
The热度 of the industry is also reflected in the source of technology research and development.——Patent End. According to data from Qichacha, as of April 24, 2026, there are 2,280 existing patents related to brain-computer interface in China. In 2025, the number of patent applications related to brain-computer interface reached 547, hitting a ten-year high, with a year-on-year increase of 35.7%. In terms of patent types, the proportion of invention patents has continued to rise, with the share of invention disclosures being about 40% in 2021 and increasing to approximately 80% by 2025. This indicates that R&D in China's brain-computer interface field is accelerating its transformation from peripheral improvements to core technological innovation.
In terms of specific companies, tech giants such as Huawei and Tencent are also actively making moves. Huawei has applied for"Signal Processing Method and Related Device" Patent Has Been Published, Applicable to the Field of Brain-Computer Interface Technology; Tencent Obtained the Patent Authorization for "Motion Control Method Based on Brain-Computer Interface and Related Equipment." Additionally, Wuhan Zhonghua Brain-Computer Technology has applied for 182 patents, and BrainLink Technology under Chengyi Tong also obtained an invention patent for "EEG Acquisition Device and EEG Acquisition Equipment."
Competitive Product Observation:
Multiple Paths in Parallel, Initial Signs of Differentiated Competitive Landscape Emerge
In China, the field of brain-computer interface medical devices has formed a relatively clear competitive landscape, with different enterprises engaging in differentiated competition based on various technological pathways and business models.
InvasiveThe semi-invasive approach is represented by companies like Steplife Medical and Boyikon. Steplife Medical, established in 2021, focuses on minimally invasive implantable brain-computer interfaces. It has independently developed ultra-flexible electrodes that are 1/100 the thickness of a hair strand and the world’s smallest wireless brain-computer implant. In the past year, it has raised over 1.1 billion yuan in cumulative financing. As the first company in the brain-computer interface field invested in by Alibaba and Tencent, its products have entered the National Medical Products Administration (NMPA) innovation "green channel." Boyikon's "Implantable Brain-Computer Interface Hand Motor Function Compensation System" obtained the world's first Class III medical device registration certificate for invasive brain-computer interfaces in March 2026.
Non-invasive approaches have attracted more explorers. Sirrem has a complete product matrix in the direction of rehabilitation robots, forming a closed-loop capability from EEG acquisition to flexible execution. OYMotion focuses on non-invasive neural signal sensing andAI parsing technology, with more than a hundred independent intellectual property rights, has been sold overseas, and the proportion of international revenue continues to increase. Xuzhishi focuses on the "AI medical + brain-computer interface" composite track, and its products have been applied in over 600 medical institutions across more than twenty provinces in China.
New technical approaches are also emerging. Gestalt Technology, as the first company in China to focus on ultrasonic brain-computer interfaces,In March 2026, Sirrem completed an angel round of financing worth 150 million yuan, setting a new record for the highest angel round financing in China's brain-computer interface field. The first product focuses on chronic pain management and has been verified for efficacy in more than 30 clinical trials.
From the overall competitive landscape, Chinese companies have demonstrated localized leading advantages in semi-invasive and non-invasive approaches. Different enterprises focus on different aspects in technical pathways, clinical directions, and business models, and have yet to form a single industry standard or top monopolistic structure.
Market Outlook:
From"Critical Leap" to "Universal Accessibility"
According to data from multiple research institutions, globallyThe BCI market size is estimated to be approximately $2.6 to $2.9 billion in 2025 and is projected to grow to about $13.86 billion by 2035, with a compound annual growth rate (CAGR) of approximately 15% to 17%. In the Chinese market, the scale is about 3.2 billion yuan in 2024 and is expected to exceed 3.8 billion yuan in 2025, with an average annual growth rate of around 20%, surpassing most mature technology sectors.
Industry analysis points out that the global brain-computer interface rehabilitation market scale is expectedBreaking through 100 billion yuan by 2030, China, with its large base of stroke, brain injury, and spinal cord injury patients, is expected to become the world's largest brain-computer interface rehabilitation market. Currently, in China's downstream brain-computer interface solutions, the medical sector accounts for about 56%, while consumer, industrial, educational, and other sectors combined account for approximately 44%. Medical rehabilitation remains the foundation of the industry.
In the short term, medical rehabilitation is the most mature field for brain-computer interface technology and the closest to widespread application; in the medium to long term, with the reduction in cost of non-invasive products and the expansion of consumer-level scenarios, brain-computer interfaces may evolve from medical devices into a key entry point for human-computer interaction. An article in the magazine "Outlook" pointed out that what might ignite the industry could be"The resonance of two directions: 'Medical rehabilitation + Non-invasive health consumption.' However, it should be noted that the current application of brain-computer interfaces in the consumer sector is still dominated by non-invasive head-worn/ear-worn devices, with functions mainly focused on sleep monitoring, concentration training, and other areas. The iteration cycle from 'usable' to 'user-friendly' and then to 'willing-to-use' remains relatively long."
The scaled growth of the industry ultimately depends on the co-evolution of several key variables: whether clinical trial data can continuously confirm safety and efficacy, and whether medical insurance coverage can be expanded from..."From 'Pilot' to 'Popularization,' and Whether the Cost of Consumer-Level Products Can Decrease to a Level That Encourages More People to Try. As the relevant official from the National Healthcare Security Administration said, 'When there’s no price, everyone is watching; once there’s a price, the entire chain starts moving.' When institutional design, technological accumulation, and capital power converge, the brain-computer interface track is forging a path toward industrialization with Chinese characteristics."
Medical Device Innovation Network Continuously Focuses on and Deeply Connects with HealthcareThe innovative force in the field of medical devices. If you are an innovative enterprise seeking technology transfer, financing support, or park establishment, or an investment institution and industrial park hoping to capture cutting-edge opportunities, feel free to contact us. Together, let's support the next innovation that will transform the medical landscape, starting from the list."Public Notice" on the Market "Application".
Contact Information:
13372107426
Previous Recommendations
Countdown to Delisting for Medical Device Leader Amid Financial Fraud Scandal
Sirrem, a medical device company in Suzhou, secures nearly 100 million yuan in financing!
